245 related articles for article (PubMed ID: 29333950)
1. Willingness to pay for an Ebola vaccine during the 2014-2016 ebola outbreak in West Africa: Results from a U.S. National sample.
Painter JE; von Fricken ME; Viana de O Mesquita S; DiClemente RJ
Hum Vaccin Immunother; 2018 Jul; 14(7):1665-1671. PubMed ID: 29333950
[TBL] [Abstract][Full Text] [Related]
2. Interest in an Ebola vaccine among a U.S. national sample during the height of the 2014-2016 Ebola outbreak in West Africa.
Painter JE; DiClemente RJ; von Fricken ME
Vaccine; 2017 Jan; 35(4):508-512. PubMed ID: 28040206
[TBL] [Abstract][Full Text] [Related]
3. Acceptability and Willingness-to-Pay for a Hypothetical Ebola Virus Vaccine in Nigeria.
Ughasoro MD; Esangbedo DO; Tagbo BN; Mejeha IC
PLoS Negl Trop Dis; 2015 Jun; 9(6):e0003838. PubMed ID: 26076007
[TBL] [Abstract][Full Text] [Related]
4. Knowledge and attitudes about Ebola vaccine among the general population in Sierra Leone.
Huo X; Shi G; Li X; Lai X; Deng L; Xu F; Chen M; Wei Q; Samba T; Liang X
Vaccine; 2016 Apr; 34(15):1767-72. PubMed ID: 26928073
[TBL] [Abstract][Full Text] [Related]
5. Attitudes about vaccines to prevent Ebola virus disease in Guinea at the end of a large Ebola epidemic: Results of a national household survey.
Irwin KL; Jalloh MF; Corker J; Alpha Mahmoud B; Robinson SJ; Li W; James NE; Sellu M; Jalloh MB; Diallo AA; Tracy L; Hajjeh R; VanSteelandt A; Bunnell R; Martel L; Raghunathan PL; Marston B;
Vaccine; 2017 Dec; 35(49 Pt B):6915-6923. PubMed ID: 28716555
[TBL] [Abstract][Full Text] [Related]
6. Implementing an Ebola Vaccine Study - Sierra Leone.
Widdowson MA; Schrag SJ; Carter RJ; Carr W; Legardy-Williams J; Gibson L; Lisk DR; Jalloh MI; Bash-Taqi DA; Kargbo SA; Idriss A; Deen GF; Russell JB; McDonald W; Albert AP; Basket M; Callis A; Carter VM; Ogunsanya KR; Gee J; Pinner R; Mahon BE; Goldstein ST; Seward JF; Samai M; Schuchat A
MMWR Suppl; 2016 Jul; 65(3):98-106. PubMed ID: 27387395
[TBL] [Abstract][Full Text] [Related]
7. Vaccines against Ebola virus.
Venkatraman N; Silman D; Folegatti PM; Hill AVS
Vaccine; 2018 Aug; 36(36):5454-5459. PubMed ID: 28780120
[TBL] [Abstract][Full Text] [Related]
8. On a path to accelerate access to Ebola vaccines: The WHO's research and development efforts during the 2014-2016 Ebola epidemic in West Africa.
Henao-Restrepo AM; Preziosi MP; Wood D; Moorthy V; Kieny MP;
Curr Opin Virol; 2016 Apr; 17():138-144. PubMed ID: 27180074
[TBL] [Abstract][Full Text] [Related]
9. Overview, Control Strategies, and Lessons Learned in the CDC Response to the 2014-2016 Ebola Epidemic.
Bell BP; Damon IK; Jernigan DB; Kenyon TA; Nichol ST; O'Connor JP; Tappero JW
MMWR Suppl; 2016 Jul; 65(3):4-11. PubMed ID: 27389903
[TBL] [Abstract][Full Text] [Related]
10. Clinical development of a recombinant Ebola vaccine in the midst of an unprecedented epidemic.
Coller BG; Blue J; Das R; Dubey S; Finelli L; Gupta S; Helmond F; Grant-Klein RJ; Liu K; Simon J; Troth S; VanRheenen S; Waterbury J; Wivel A; Wolf J; Heppner DG; Kemp T; Nichols R; Monath TP
Vaccine; 2017 Aug; 35(35 Pt A):4465-4469. PubMed ID: 28647166
[TBL] [Abstract][Full Text] [Related]
11. [Ebola vaccine and treatment].
Takada A
Uirusu; 2015; 65(1):61-70. PubMed ID: 26923959
[TBL] [Abstract][Full Text] [Related]
12. Infectious disease. Ebola vaccine: little and late.
Cohen J
Science; 2014 Sep; 345(6203):1441-2. PubMed ID: 25237082
[No Abstract] [Full Text] [Related]
13. Unprecedented pace and partnerships: the story of and lessons learned from one Ebola vaccine program.
Gupta SB; Coller BA; Feinberg M
Expert Rev Vaccines; 2018 Oct; 17(10):913-923. PubMed ID: 30269612
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial.
Henao-Restrepo AM; Longini IM; Egger M; Dean NE; Edmunds WJ; Camacho A; Carroll MW; Doumbia M; Draguez B; Duraffour S; Enwere G; Grais R; Gunther S; Hossmann S; Kondé MK; Kone S; Kuisma E; Levine MM; Mandal S; Norheim G; Riveros X; Soumah A; Trelle S; Vicari AS; Watson CH; Kéïta S; Kieny MP; Røttingen JA
Lancet; 2015 Aug; 386(9996):857-66. PubMed ID: 26248676
[TBL] [Abstract][Full Text] [Related]
15. Immunology and evolvement of the adenovirus prime, MVA boost Ebola virus vaccine.
Zhou Y; Sullivan NJ
Curr Opin Immunol; 2015 Aug; 35():131-6. PubMed ID: 26247875
[TBL] [Abstract][Full Text] [Related]
16. The Ebola outbreak, 2013-2016: old lessons for new epidemics.
Coltart CE; Lindsey B; Ghinai I; Johnson AM; Heymann DL
Philos Trans R Soc Lond B Biol Sci; 2017 May; 372(1721):. PubMed ID: 28396469
[TBL] [Abstract][Full Text] [Related]
17. Travel and Border Health Measures to Prevent the International Spread of Ebola.
Cohen NJ; Brown CM; Alvarado-Ramy F; Bair-Brake H; Benenson GA; Chen TH; Demma AJ; Holton NK; Kohl KS; Lee AW; McAdam D; Pesik N; Roohi S; Smith CL; Waterman SH; Cetron MS
MMWR Suppl; 2016 Jul; 65(3):57-67. PubMed ID: 27390092
[TBL] [Abstract][Full Text] [Related]
18. Infection Prevention and Control for Ebola in Health Care Settings - West Africa and United States.
Hageman JC; Hazim C; Wilson K; Malpiedi P; Gupta N; Bennett S; Kolwaite A; Tumpey A; Brinsley-Rainisch K; Christensen B; Gould C; Fisher A; Jhung M; Hamilton D; Moran K; Delaney L; Dowell C; Bell M; Srinivasan A; Schaefer M; Fagan R; Adrien N; Chea N; Park BJ
MMWR Suppl; 2016 Jul; 65(3):50-6. PubMed ID: 27390018
[TBL] [Abstract][Full Text] [Related]
19. WHO ready to deploy Ebola vaccine in disease outbreak.
Gulland A
BMJ; 2017 May; 357():j2454. PubMed ID: 28533207
[No Abstract] [Full Text] [Related]
20. Experiences of Response Measures against the 4 Suspected Cases of Ebola Virus Disease from West Africa in the National Center for Global Health and Medicine, Tokyo, Japan.
Kutsuna S; Yamamoto K; Takeshita N; Hayakawa K; Kato Y; Kanagawa S; Sugiki Y; Ohmagari N
Jpn J Infect Dis; 2018 Jan; 71(1):62-64. PubMed ID: 29093311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
